These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 33051344

  • 1. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.
    Toorop AA, van Lierop ZYG, Strijbis EEM, Teunissen CE, Petzold A, Wattjes MP, Barkhof F, de Jong BA, van Kempen ZLE, Killestein J.
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33051344
    [Abstract] [Full Text] [Related]

  • 2. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mancinelli CR, Scarpazza C, Cordioli C, De Rossi N, Rasia S, Turrini MV, Capra R.
    Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
    [Abstract] [Full Text] [Related]

  • 3. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
    Puig-Casadevall M, Álvarez-Bravo G, Varela AQ, Robles-Cedeño R, Sànchez Cirera L, Miguela A, Laguillo G, Montalban X, Hauser SL, Ramió-Torrentà L.
    Eur J Neurol; 2023 Oct; 30(10):3357-3361. PubMed ID: 37485841
    [Abstract] [Full Text] [Related]

  • 4. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
    Fabis-Pedrini MJ, Xu W, Burton J, Carroll WM, Kermode AG.
    J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
    [Abstract] [Full Text] [Related]

  • 5. Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
    Ercan MB, Kocer B, Altiparmak T, Arslan I.
    Mult Scler; 2024 May; 30(6):760-762. PubMed ID: 38385206
    [No Abstract] [Full Text] [Related]

  • 6. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP.
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [Abstract] [Full Text] [Related]

  • 7. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ.
    Neurology; 2012 May 01; 78(18):1390-3. PubMed ID: 22517104
    [Abstract] [Full Text] [Related]

  • 8. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 May 01; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Marousi S, Travasarou M, Karageorgiou CE, Gheuens S, Koralnik IJ.
    Neurology; 2012 Nov 20; 79(21):2160; author reply 2160. PubMed ID: 23170016
    [No Abstract] [Full Text] [Related]

  • 10. Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
    Smoot K, Marginean H, Gervasi-Follmar T, Chen C, Repovic P, Cohan S.
    Mult Scler; 2023 Jul 20; 29(8):956-966. PubMed ID: 37317841
    [Abstract] [Full Text] [Related]

  • 11. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J.
    Mult Scler; 2015 Apr 20; 21(4):481-4. PubMed ID: 25078275
    [Abstract] [Full Text] [Related]

  • 12. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
    Kinner M, Prehn C, Schneider R, Schroeder C, Kolb E, Gold R, Hoepner R, Chan A.
    Eur J Neurol; 2021 Mar 20; 28(3):921-927. PubMed ID: 33085811
    [Abstract] [Full Text] [Related]

  • 13. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T.
    J Neuropathol Exp Neurol; 2012 Jul 20; 71(7):604-17. PubMed ID: 22710964
    [Abstract] [Full Text] [Related]

  • 14. Safety and effectiveness of disease-modifying therapies after switching from natalizumab.
    Zeineddine M, Al-Roughani R, Farouk Ahmed S, Khoury S, El-Ayoubi N, Al-Mahdawi A, Al-Khabouri J, Al-Asmi A, Chentouf A, Inshasi J, Gouider R, Mrabet S, Shalaby N, Massouh J, Mohamed Ramzy Hasan Mohamed F, Al-Hajje A, Salameh P, Dimassi H, Boumediene F, Yamout B.
    Mult Scler; 2024 Jul 20; 30(8):1026-1035. PubMed ID: 39054846
    [Abstract] [Full Text] [Related]

  • 15. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.
    Mult Scler; 2015 Oct 20; 21(12):1600-3. PubMed ID: 25662344
    [Abstract] [Full Text] [Related]

  • 16. Progressive multifocal leukoencephalopathy and natalizumab.
    Hellwig K, Gold R.
    J Neurol; 2011 Nov 20; 258(11):1920-8. PubMed ID: 21647730
    [Abstract] [Full Text] [Related]

  • 17. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
    Metz I, Radue EW, Oterino A, Kümpfel T, Wiendl H, Schippling S, Kuhle J, Sahraian MA, Gray F, Jakl V, Häusler D, Brück W.
    Acta Neuropathol; 2012 Feb 20; 123(2):235-45. PubMed ID: 22057786
    [Abstract] [Full Text] [Related]

  • 18. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.
    Mult Scler; 2013 Dec 20; 19(14):1826-40. PubMed ID: 24192217
    [Abstract] [Full Text] [Related]

  • 19. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
    van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.
    Mult Scler; 2017 Jun 20; 23(7):995-999. PubMed ID: 28112019
    [Abstract] [Full Text] [Related]

  • 20. Deaths and disability from natalizumab are no longer tolerable: Commentary.
    Hutchinson M.
    Mult Scler; 2012 Aug 20; 18(8):1073. PubMed ID: 22807472
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.